Title: INDOLE COMPOUNDS

Abstract: Compounds of formula (I) or a pharmaceutically acceptable derivative thereof, (formula I) wherein X, R, R', and R' are as defined in the specification, a process for the preparation of such compounds, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine.

WO 2008/006790 A1
INDOLE COMPOUNDS

This invention relates to indole compounds, to processes for their preparation, to pharmaceutical compositions containing them and to their use in medicine, in particular their use in the treatment of conditions mediated by the action of PGE₂ at the EP₁ receptor.

The EP₁ receptor is a 7-transmembrane receptor and its natural ligand is the prostaglandin PGE₂. PGE₂ also has affinity for the other EP receptors (types EP₂, EP₃ and EP₄). The EP₁ receptor is associated with smooth muscle contraction, pain (in particular inflammatory, neuropathic and visceral), inflammation, allergic activities, renal regulation and gastric or enteric mucus secretion. We have now found a novel group of compounds which bind with high affinity to the EP₁ receptor.

A number of review articles describe the characterization and therapeutic relevance of the prostanoid receptors as well as the most commonly used selective agonists and antagonists: Eicosanoids; From Biotechnology to Therapeutic Applications, Folco, Samuelsson, Maclouf, and Velo eds, Plenum Press, New York, 1996, chap. 14, 137-154 and Journal of Lipid Mediators and Cell Signalling, 1996, 14, 83-87 and Prostanoid Receptors, Structure, Properties and Function, S Narumiya et al, Physiological Reviews 1999, 79(4), 1193-126. An article from The British Journal of Pharmacology, 1994, 112, 735-740 suggests that Prostaglandin E₂ (PGE₂) exerts allodynia through the EP₁ receptor subtype and hyperalgesia through EP₂ and EP₃ receptors in the mouse spinal cord. Furthermore an article from The Journal of Clinical Investigation, 2001, 107 (3), 325 shows that in the EP₁ knock-out mouse pain-sensitivity responses are reduced by approximately 50%. Two papers from Anesthesia and Analgesia have shown that (2001, 93, 1012-7) an EP₁ receptor antagonist (ONO-8711) reduces hyperalgesia and allodynia in a rat model of chronic constriction injury, and that (2001, 92, 233-238) the same antagonist inhibits mechanical hyperalgesia in a rodent model of post-operative pain. S. Sarkar et al in Gastroenterology, 2003, 124(1), 18-25 demonstrate the efficacy of EP₁ receptor antagonists in the treatment of visceral pain in a human model of hypersensitivity. Thus, selective prostaglandin ligands, agonists or antagonists, depending on which prostaglandin E receptor subtype is being considered, have anti-inflammatory, antipyretic and analgesic properties similar to a conventional non-steroidal anti-inflammatory drug, and in addition, inhibit hormone-induced uterine contractions and have anti-cancer effects. These compounds have a diminished ability to induce some of the mechanism-based side effects of NSAIDs which are indiscriminate cyclooxygenase inhibitors. In particular, the compounds have a reduced potential for gastrointestinal toxicity, a reduced potential for renal side effects, a reduced effect on bleeding times and a lessened ability to induce asthma attacks in aspirin-sensitive asthmatic subjects. Moreover, by sparing potentially beneficial prostaglandin pathways, these agents may have enhanced efficacy over NSAIDS and/or COX-2 inhibitors.
In The American Physiological Society (1994, 267, R289-R-294), studies suggest that PGE\(_2\)-induced hyperthermia in the rat is mediated predominantly through the EP\(_1\) receptor.


It is now suggested that a novel group of indole and indazole derivatives indicated to be useful in treating conditions mediated by the action of PGE\(_2\) at EP\(_1\) receptors. Such conditions include pain, or inflammatory, immunological, bone, neurodegenerative or renal disorders.

Accordingly the present invention provides one or more chemical entities selected from compounds of formula (I):

![Chemical Structure](image)

(I)
wherein
R\(^1\) represents hydrogen, methyl, -CF\(_3\), chlorine, fluorine or bromine;
R\(^2\) represents ethyl, propyl, isopropyl, isobutyl, -CH\(_2\)-t-butyl, -(CH\(_2\))\(_2\)-t-butyl, optionally substituted -CH\(_2\)-phenyl, -CH\(_2\)-CF\(_3\) or -CO-isopropyl;
X represents CH or N;
R\(^3\) represents a group of formula (i)-(ix):

(i) \[
\begin{array}{c}
\text{O} \\
\text{N} \\
\text{R}^4
\end{array}
\]

(ii) \[
\begin{array}{c}
\text{S} \\
\text{N} \\
\text{R}^4
\end{array}
\]

(iii) \[
\begin{array}{c}
\text{N} \\
\text{COOH} \\
\text{R}^4
\end{array}
\]

(iv) \[
\begin{array}{c}
\text{N} \\
\text{R}^4
\end{array}
\]

(v) \[
\begin{array}{c}
\text{S} \\
\text{R}^4
\end{array}
\]

(vi) \[
\begin{array}{c}
\text{S} \\
\text{R}^4
\end{array}
\]

(vii) \[
\begin{array}{c}
\text{N} \\
\text{R}^4
\end{array}
\]

(viii) \[
\begin{array}{c}
\text{S} \\
\text{R}^4 \\
\text{COOH}
\end{array}
\]

or

(ix) \[
\begin{array}{c}
\text{S} \\
\text{R}^4
\end{array}
\]

15 R\(^4\) represents -COOH, -CO-NH-SO\(_2\)-R\(^5\) or tetrazole;
R\(^5\) represents C\(_{1-3}\) alkyl, optionally substituted phenyl or 2,4-dimethylisoxazol-4-yI;
such that when R\(^1\) represents hydrogen, R\(^2\) represents isobutyl;
or derivatives thereof.

Optional substituents for phenyl are selected from optionally substituted C\(_{1-5}\)alkyl (e.g. methyl),
amino, optionally substituted C\(_{1-5}\)alkylamino, hydroxy, HO-C\(_{1-4}\)alkyl (e.g. HOCH\(_2\)) and halogen
(e.g. fluorine).

Suitably, R\(^1\) represents bromine or chlorine. In a further embodiment, R\(^1\) represents
chlorine.

Suitably, R\(^2\) represents ethyl, propyl, isopropyl, isobutyl, -CH\(_2\)-t-butyl, -(CH\(_2\))\(_2\)-t-butyl,
benzyl, -CH\(_2\)-CF\(_3\) or -CO-isopropyl.

30 Suitably, X represents CH.

Suitably, R\(^3\) represents a group of formula (ii):

(ii) \[
\begin{array}{c}
\text{S} \\
\text{R}^4
\end{array}
\]
Suitably, R⁴ represents –COOH or -CO-NH-SO₂-R⁶ (e.g. -CO-NH-SO₂-phenyl). In one embodiment, R⁴ represents –COOH.

Compounds of formula (I) include the compounds of Examples 1 to 24 and derivatives thereof.

Particular compounds of formula (I) include the compounds of Examples 4, 5, 6, 11, 12, 13, 17 and 19.

A particular compound is 6-[6-chloro-3-(2-methylpropyl)-1H-indol-1-yl]-2-pyridinecarboxylic acid.

Certain compounds of the Examples are selective for EP₁ over EP₃. Certain compounds of the Examples have greater than 30 fold selectivity.

Derivatives of the compound of formula (I) include salts, solvates (including hydrates), solvates (including hydrates) of salts, esters and polymorphs of the compound of formula (I). Derivatives of the compounds of formula (I) include pharmaceutically acceptable derivatives.

It is to be understood that the present invention encompasses all isomers of formula (I) and their pharmaceutically acceptable derivatives, including all geometric, tautomeric and optical forms, and mixtures thereof (e.g. racemic mixtures). Where additional chiral centres are present in compounds of formula (I), the present invention includes within its scope all possible diastereoisomers, including mixtures thereof. The different isomeric forms may be separated or resolved one from the other by conventional methods, or any given isomer may be obtained by conventional synthetic methods or by stereospecific or asymmetric syntheses.

The present invention also includes isotopically-labelled compounds, which are identical to the compounds of formula (I), except that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, iodine, and chlorine, such as ²H, ³H, ¹¹C, ¹⁴C, ¹⁸F, ³⁵S, ¹²³I and ¹²⁵I.

Compounds of the present invention and pharmaceutically acceptable derivatives (e.g. salts) of said compounds that contain the aforementioned isotopes and/or other isotopes of other atoms are within the scope of the present invention. Isotopically-labelled compounds of the present invention, for example those into which radioactive isotopes such as ³H and/or ¹⁴C are incorporated, are useful in drug and/or substrate tissue distribution assays. ³H and ¹⁴C are considered useful due to their ease of preparation and
detectability. $^{11}$C and $^{18}$F isotopes are considered useful in PET (positron emission tomography), and $^{125}$I isotopes are considered useful in SPECT (single photon emission computerized tomography), all useful in brain imaging. Substitution with heavier isotopes such as $^3$H can afford certain therapeutic advantages resulting from greater metabolic stability, for example increased \textit{in vivo} half-life or reduced dosage requirements and, hence, are considered useful in some circumstances. Isotopically labelled compounds of formula (I) of this invention can generally be prepared by carrying out the procedures disclosed in the Schemes and/or in the Examples below, by substituting a readily available isotopically labelled reagent for a non-isotopically labelled reagent.

The following definitions are used herein unless otherwise indicated.

The term "pharmaceutically acceptable derivative" means any pharmaceutically acceptable salt, solvate, ester, or solvate of salt or ester of the compounds of formula (I), or any other compound which upon administration to the recipient is capable of providing (directly or indirectly) a compound of formula (I). In one aspect the term "pharmaceutically acceptable derivative" means any pharmaceutically acceptable salt, solvate or solvate of salt. In an alternative aspect the term "pharmaceutically acceptable derivative" means any pharmaceutically acceptable salt.

It will be appreciated that, for pharmaceutical use, the derivatives referred to above will be pharmaceutically acceptable derivatives, but other derivatives may find use, for example in the preparation of compounds of formula (I) and the pharmaceutically acceptable derivatives thereof.

Pharmaceutically acceptable salts include those described by Berge, Bighley and Monkhouse, \textit{J. Pharm. Sci.}, 1977, \textit{66}, 1-19. The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable bases including inorganic bases and organic bases. Salts derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc, and the like. Salts derived from pharmaceutically acceptable organic bases include salts of primary, secondary, and tertiary amines; substituted amines including naturally occurring substituted amines; and cyclic amines. Particular pharmaceutically acceptable organic bases include arginine, betaine, caffeine, choline, N,N′-dibenzylethylendiamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethyl-morpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, procaaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tris(hydroxymethyl)aminomethane (TRIS, trometamol) and the like. Salts may also be formed from basic ion exchange resins, for example polyamine resins. When the compound of the present invention is basic, salts may be prepared from pharmaceutically acceptable acids, including inorganic and organic acids. Such acids include acetic, benzenesulfonic, benzoic,
camphorsulfonic, citric, ethanesulfonic, ethanedisulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, pamoic, pantothenic, phosphoric, propionic, succinic, sulfuric, tartaric, p-toluenesulfonic acid, and the like.

The compounds of formula (I) may be prepared in crystalline or non-crystalline form, and may be optionally hydrated or solvated. This invention includes in its scope stoichiometric hydrates as well as compounds containing variable amounts of water.

Suitable solvates include pharmaceutically acceptable solvates, such as hydrates.

Solvates include stoichiometric solvates and non-stoichiometric solvates.

Compounds of formula (I) can be prepared as set forth in the following schemes and in the examples. The following processes form another aspect of the present invention.

Compounds of formula (I) wherein \( R^2 \) represents ethyl, propyl, isobutyl, \(-\mathrm{CH}_2\mathrm{-t-butyl}, \mathrm{-CH}_2\mathrm{-t-butyl}, \) optionally substituted \(-\mathrm{CH}_2\)-phenyl or \(-\mathrm{CH}_2\mathrm{-CF}_3, R^2 \) represents a group of formula (ii). \(X\) represents \(\mathrm{CH}\) and \(R^4\) represents \(-\mathrm{COOH}\) may be prepared by the general route shown in Scheme 1 below:

\[ \text{Scheme 1} \]

\[ \text{Diagram showing chemical synthesis steps} \]

wherein \( R^1 \) is as defined above, \( R \) represents methyl, ethyl, isopropyl, \( t\)-butyl, \(-\mathrm{CH}_2\mathrm{-t-butyl}, \) optionally substituted phenyl or \( \mathrm{CF}_3, L^1 \) represents a suitable leaving group such as a halogen atom (e.g. chlorine) and \( L^2 \) represents a suitable leaving group such as a halogen atom (e.g. bromine).
Step (i) typically comprises reaction of a compound of formula (II) with a compound of formula L¹-CO-R in the presence of suitable reagents, such as methyl magnesium bromide and zinc chloride.

Step (ii) typically comprises a reduction reaction in the presence of a suitable reducing agent, e.g. lithium aluminium hydride or sodium borohydride.

Step (iii) typically comprises a Buchwald coupling reaction between a compound of formula (IV) and a compound of formula (V) in the presence of a suitable catalyst e.g. copper (I) iodide and a suitable base e.g. potassium phosphate and a suitable amine, in the presence of a suitable solvent e.g. toluene.

Step (iv) typically comprises treatment of a compound of formula (VI) with sodium hydroxide.

Compounds of formula (I) wherein R² is CH₂CF₃ may also be prepared in accordance with the methods as described in the examples.

Compounds of formula (I) wherein R³ is other than a group of formula (ii) may be prepared by analogous procedures to those described in Scheme 1, for example as described in the Examples.

Compounds of formula (I) wherein R² represents isopropyl, R³ represents a group of formula (ii) and R⁴ represents –COOH may be prepared by the general route shown in Scheme 2 below:
wherein $R^1$ and $L^2$ are as defined above.

Step (i) typically comprises reaction of a compound of formula (VII) with a suitable alkylating reagent, such as 1-bromo-3-methyl but-2-ene, in the presence of a suitable base e.g. lithium diisopropylamide.

Step (ii) typically comprises an intramolecular Heck coupling reaction in the presence of a suitable catalyst e.g. palladium acetate in a suitable solvent e.g. dimethylformamide.

Steps (iii) and (iv) may be performed in an analogous manner to steps (iii) and (iv) in Scheme 1.

Compounds of formula (I) wherein $X$ represents $N$, $R^3$ represents a group of formula (ii) and $R^4$ represents $-COOH$ may be prepared by the general route shown in Scheme 3 below.
wherein R¹, R² and L² are as defined above.

Step (i) comprises reaction of a compound of formula (XI) with a Grignard reagent of formula R²-MgBr in a suitable solvent e.g. tetrahydrofuran.

Step (ii) comprises reaction of a compound of formula (XII) with hydrazine hydrate in a suitable solvent e.g. ethanol.

Step (iii) comprises intramolecular cyclisation in a suitable solvent e.g. ethylene glycol at an elevated temperature.

Steps (iv) and (v) may be performed in an analogous manner to steps (iii) and (iv) in Schemes 1 and 2.

Compounds of formula (I) wherein R² represents ethyl, propyl, isobutyl, -CH₂-t-butyl, -(CH₃)₂-t-butyl, optionally substituted -CH₂-phenyl or -CH₂-CF₃, R³ represents a group of formula (iii), X represents CH and R⁴ represents -COOH may be prepared by the general route shown in Scheme 4 below.
wherein \( R^1 \) and \( R \) are as defined above and \( L^3 \) represents a suitable leaving group such as a halogen atom (e.g. bromine).

Step (i) typically comprises treatment of a compound of formula (IV) with a compound of formula (XVI) in the presence of a suitable base e.g. sodium hydride in a suitable solvent e.g. dimethylformamide.

Step (ii) may be performed in an analogous manner to step (iv) in Schemes 1 and 2.

It will be appreciated that compounds of formula (I) wherein \( R^3 \) represents groups of formulae (i) and (iv) to (ix) may be prepared in an analogous manner to the procedure described in Scheme 1 for compounds wherein \( R^3 \) represents a group of formula (ii).

It will be appreciated to those skilled in the art that compounds of formula (I) wherein \( R^4 \) represents -\( \text{CONHSO}_2R^5 \) or tetrazole may be prepared from compounds of formula (I)\(^a\) by standard reaction sequences. For example, derivatives wherein \( R^4 \) represents -\( \text{CONHSO}_2R^5 \) may be prepared from compounds of formula (I)\(^a\) by conversion to the acid chloride, for example by reaction with thionyl chloride or oxalyl chloride, in the presence of DMF, in a suitable solvent, such as DCM, followed by reaction with a sulphonamide.

Alternative conditions include reaction of a carboxylic acid of formula (I)\(^a\) with a sulphonamide in a solvent, such as THF or DCM, in the presence of EDC and DMAP. Compounds of formula (I) where \( R^4 \) is tetrazole may be formed from the corresponding carboxylic acid (i.e. compounds of formula (I)\(^a\), (I)\(^b\), (I)\(^c\) or (I)\(^d\)) by converting the carboxylic acid to the primary amide (for example by reaction with sulfonyl chloride followed by ammonia) followed by dehydration of the amide to the nitrile (for example by heating in phosphorous oxychloride) followed by reaction with azide.

Certain substituents in any of the reaction intermediates and compounds of formula (I) may be converted to other substituents by conventional methods known to those skilled in the art. Examples of such transformations include the hydrolysis of esters and esterification of carboxylic acids. Such transformations are well known to those skilled in the art and are described in for example, Richard Larock, *Comprehensive Organic Transformations*, 2nd edition, Wiley-VCH, ISBN 0-471-19031-4.

It will be appreciated by those skilled in the art that it may be necessary to protect certain reactive substituents during some of the above procedures. The skilled person will recognise when a protecting group is required. Standard protection and deprotection techniques, such as those described in Greene T.W., 'Protective groups in organic synthesis', New York, Wiley (1981), can be used. For example, carboxylic acid groups can be protected as esters. Deprotection of such groups is achieved using conventional procedures known in the art. It will be appreciated that protecting groups may be interconverted by conventional means.
Compounds of formula (II), (V), (VII), (XI) and (XVI) are either commercially available, or may be prepared by known methods.

The compounds of the invention bind to the EP\(_1\) receptor and are antagonists of this receptor. They are therefore considered useful in treating conditions mediated by the action of PGE\(_2\) at EP\(_1\) receptors.

One condition mediated by the action of PGE\(_2\) at EP\(_1\) receptors is pain, including acute pain, chronic pain, chronic articular pain, musculoskeletal pain, neuropathic pain, inflammatory pain, visceral pain, pain associated with cancer, pain associated with migraine, tension headache and cluster headaches, pain associated with functional bowel disorders, lower back and neck pain, pain associated with sprains and strains, sympathetically maintained pain; myositis, pain associated with influenza or other viral infections such as the common cold, pain associated with rheumatic fever, pain associated with myocardial ischemia, post-operative pain, headache, toothache and dysmenorrhea.

Chronic articular pain conditions include rheumatoid arthritis, osteoarthritis, rheumatoid spondylitis, gouty arthritis and juvenile arthritis.

Pain associated with functional bowel disorders includes non-ulcer dyspepsia, non-cardiac chest pain and irritable bowel syndrome.

Neuropathic pain syndromes include: diabetic neuropathy, sciatica, non-specific lower back pain, multiple sclerosis pain, fibromyalgia, HIV-related neuropathy, post-herpetic neuralgia, trigeminal neuralgia, and pain resulting from physical trauma, amputation, cancer, toxins or chronic inflammatory conditions. In addition, neuropathic pain conditions include pain associated with normally non-painful sensations such as "pins and needles" (paraesthesias and dyesthesias), increased sensitivity to touch (hyperesthesia), painful sensation following innocuous stimulation (dynamic, static, thermal or cold allodynia), increased sensitivity to noxious stimuli (thermal, cold, mechanical hyperalgesia), continuing pain sensation after removal of the stimulation (hyperpathia) or an absence of or deficit in selective sensory pathways (hypoalgesia).

Other conditions mediated by the action of PGE\(_2\) at EP\(_1\) receptors include fever, inflammation, immunological diseases, abnormal platelet function diseases (e.g. occlusive vascular diseases), impotence or erectile dysfunction; bone disease characterised by abnormal bone metabolism or resorption; hemodynamic side effects of non-steroidal anti-inflammatory drugs (NSAID's) and cyclooxygenase-2 (COX-2) inhibitors, cardiovascular diseases; neurodegenerative diseases and neurodegeneration, neurodegeneration following trauma, tinnitus, dependence on a dependence-inducing agent such as opioids (e.g. morphine), CNS depressants (e.g. ethanol), psychostimulants (e.g. cocaine) and nicotine; complications of Type I diabetes, kidney dysfunction, liver dysfunction (e.g.
hepatitis, cirrhosis), gastrointestinal dysfunction (e.g. diarrhoea), colon cancer, overactive bladder and urge incontinence.

Inflammatory conditions include skin conditions (e.g. sunburn, burns, eczema, dermatitis, psoriasis), ophthalmic diseases such as glaucoma, retinitis, retinopathies, uveitis and of acute injury to the eye tissue (e.g. conjunctivitis), inflammatory lung disorders (e.g. asthma, bronchitis, emphysema, allergic rhinitis, respiratory distress syndrome, pigeon fancier’s disease, farmer’s lung, chronic obstructive pulmonary disease (COPD); gastrointestinal tract disorders (e.g. aphthous ulcer, Crohn’s disease, atopic gastritis, gastritis varialoforme, ulcerative colitis, coeliac disease, regional ileitis, irritable bowel syndrome, inflammatory bowel disease, gastrointestinal reflux disease); organ transplantation and other conditions with an inflammatory component such as vascular disease, migraine, periarteritis nodosa, thyroiditis, aplastic anaemia, Hodgkin’s disease, sclerodema, myaesthesia gravis, multiple sclerosis, sorcoidosis, nephrotic syndrome, Bechet’s syndrome, gingivitis, myocardial ischemia, pyrexia, systemic lupus erythematousus, polymyositis, tendinitis, bursitis, and Sjogren’s syndrome.

Immunological diseases include autoimmune diseases, immunological deficiency diseases or organ transplantation. The compounds of formula (I) are also effective in increasing the latency of HIV infection.

Bone diseases characterised by abnormal bone metabolism or resorption include osteoporosis (especially postmenopausal osteoporosis), hyper-calcemia, hyperparathyroidism, Paget’s bone diseases, osteolysis, hypercalcemia of malignancy with or without bone metastases, rheumatoid arthritis, periodontitis, osteoarthritis, ostealgia, osteopenia, cancer cachexia, calculus, lithiasis (especially urolithiasis), solid carcinoma, gout and ankylosing spondylitis, tendinitis and bursitis.

Cardiovascular diseases include hypertension or myocardial ischemia; functional or organic venous insufficiency; varicose therapy; haemorrhoids; and shock states associated with a marked drop in arterial pressure (e.g. septic shock).

Neurodegenerative diseases include dementia, particularly degenerative dementia (including senile dementia, Alzheimer’s disease, Pick’s disease, Huntington’s chorea, Parkinson’s disease and Creutzfeldt-Jakob disease, ALS, motor neuron disease); vascular dementia (including multi-infarct dementia); as well as dementia associated with intracranial space occupying lesions; trauma; infections and related conditions (including HIV infection); metabolism; toxins; anoxia and vitamin deficiency; and mild cognitive impairment associated with ageing, particularly Age Associated Memory Impairment.

The compounds of formula (I) are also considered useful in the treatment of neuroprotection and in the treatment of neurodegeneration following trauma such as
stroke, cardiac arrest, pulmonary bypass, traumatic brain injury, spinal cord injury or the like.

Complications of Type 1 diabetes include diabetic microangiopathy, diabetic retinopathy, diabetic nephropathy, macular degeneration, glaucoma, nephrotic syndrome, aplastic anaemia, uveitis, Kawasaki disease and sarcoidosis.

Kidney dysfunction includes nephritis, particularly mesangial proliferative glomerulonephritis and nephritic syndrome.

The compounds of formula (I) are also considered useful for the preparation of a drug with diuretic action.

It is to be understood that reference to treatment includes both treatment of established symptoms and prophylactic treatment, unless explicitly stated otherwise.

According to a further aspect of the invention, we provide a compound of formula (I) or a pharmaceutically acceptable derivative thereof for use in human or veterinary medicine.

According to another aspect of the invention, we provide a compound of formula (I) or a pharmaceutically acceptable derivative thereof for use in the treatment of a condition which is mediated by the action of PGE$_2$ at EP$_1$ receptors.

According to a further aspect of the invention, we provide a method of treating a human or animal subject suffering from a condition which is mediated by the action of PGE$_2$ at EP$_1$ receptors which comprises administering to said subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable derivative thereof.

According to a further aspect of the invention we provide a method of treating a human or animal subject suffering from a pain, inflammatory, immunological, bone, neurodegenerative or renal disorder, which method comprises administering to said subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable derivative thereof.

According to a yet further aspect of the invention we provide a method of treating a human or animal subject suffering from inflammatory pain, neuropathic pain or visceral pain which method comprises administering to said subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable derivative thereof.

According to another aspect of the invention, we provide the use of a compound of formula (I) or a pharmaceutically acceptable derivative thereof for the manufacture of a
medicament for the treatment of a condition which is mediated by the action of PGE$_2$ at EP$_1$ receptors.

According to another aspect of the invention we provide the use of a compound of formula (I) or a pharmaceutically acceptable derivative thereof for the manufacture of a medicament for the treatment or prevention of a condition such as a pain, inflammatory, immunological, bone, neurodegenerative or renal disorder.

According to another aspect of the invention we provide the use of a compound of formula (I) or a pharmaceutically acceptable derivative thereof for the manufacture of a medicament for the treatment or prevention of a condition such as inflammatory pain, neuropathic pain or visceral pain.

The compounds of formula (I) and their pharmaceutically acceptable derivatives are conveniently administered in the form of pharmaceutical compositions. Such compositions may conveniently be presented for use in conventional manner in admixture with one or more physiologically acceptable carriers or excipients.

Thus, in another aspect of the invention, we provide a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable derivative thereof.

A proposed daily dosage of compounds of formula (I) or their pharmaceutically acceptable derivatives for the treatment of man is from 0.01 to 80 mg/kg body weight, more particularly 0.01 to 30 mg/kg body weight per day, for example 0.1 to 10 mg/kg body weight per day, which may be administered as a single or divided dose, for example one to four times per day. The dose range for adult human beings is generally from 8 to 4000 mg/day, more particularly from 8 to 2000 mg/day, such as from 20 to 1000 mg/day, for example 35 to 200 mg/day.

The precise amount of the compounds of formula (I) administered to a host, particularly a human patient, will be the responsibility of the attendant physician. However, the dose employed will depend on a number of factors including the age and sex of the patient, the precise condition being treated and its severity, and the route of administration.

The compounds of formula (I) and their pharmaceutically acceptable derivatives may be formulated for administration in any suitable manner. They may be formulated for administration by inhalation or for oral, topical, transdermal or parenteral administration. The pharmaceutical composition may be in a form such that it can effect controlled release of the compounds of formula (I) and their pharmaceutically acceptable derivatives.
For oral administration, the pharmaceutical composition may take the form of, for example, tablets (including sub-lingual tablets), capsules, powders, solutions, syrups or suspensions prepared by conventional means with acceptable excipients.

For transdermal administration, the pharmaceutical composition may be given in the form of a transdermal patch, such as a transdermal iontophoretic patch.

For parenteral administration, the pharmaceutical composition may be given as an injection or a continuous infusion (e.g. intravenously, intravascularly or subcutaneously).

The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles and may contain formulatory agents such as suspending, stabilising and/or dispersing agents. For administration by injection these may take the form of a unit dose presentation or as a multidose presentation preferably with an added preservative. Alternatively for parenteral administration the active ingredient may be in powder form for reconstitution with a suitable vehicle.

The compounds of the invention may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds of the invention may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

The EP1 receptor compounds for use in the instant invention may be used in combination with other therapeutic agents, for example COX-2 (cyclooxygenase-2) inhibitors, such as celecoxib, deracoxib, rofecoxib, valdecoxib, parecoxib, COX-189 or 2-(4-ethoxy-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo[1,5-b]pyridazine (WO99/012930); 5-lipoxygenase inhibitors; NSAIDs (non-steroidal anti-inflammatory drugs) such as diclofenac, indomethacin, nabumetone or ibuprofen; leukotriene receptor antagonists; DMARDs (disease modifying anti-rheumatic drugs) such as methotrexate; adenosine A1 receptor agonists; sodium channel blockers, such as lamotrigine; NMDA (N-methyl-D-aspartate) receptor modulators, such as glycine receptor antagonists; ligands for the αδ-subunit of voltage gated calcium channels, such as gabapentin and pregabalin; tricyclic antidepressants such as amitriptyline; neurone stabilising antiepileptic drugs; monoaminergic uptake inhibitors such as venlafaxine; opioid analgesics; local anaesthetics; 5HT1 agonists, such as triptans, for example sumatriptan, naratriptan, zolmitriptan, eletriptan, frovatriptan, almotriptan or rizatriptan; nicotinic acetyl choline (nACH) receptor modulators; glutamate receptor modulators, for example modulators of the NR2B subtype; EPα receptor ligands; EPβ receptor ligands; EP3 receptor ligands; EP4 agonists and EP2 agonists; EP4 antagonists; EP2 antagonists and EP3 antagonists; cannabanoid receptor ligands; bradynkinin receptor ligands; vaniloid receptor ligand; and purinergic receptor ligands, including antagonists at P2X3, P2X2, P2X4, P2X7 or P2X4/7. When the
compounds are used in combination with other therapeutic agents, the compounds may be administered either sequentially or simultaneously by any convenient route.


The invention thus provides, in a further aspect, a combination comprising a compound of formula (I) or a pharmaceutically acceptable derivative thereof together with a further therapeutic agent or agents.

The combinations referred to above may conveniently be presented for use in the form of a pharmaceutical formulation and thus pharmaceutical formulations comprising a combination as defined above together with a pharmaceutically acceptable carrier or excipient comprise a further aspect of the invention. The individual components of such combinations may be administered either sequentially or simultaneously in separate or combined pharmaceutical formulations.

When a compound of formula (I) or a pharmaceutically acceptable derivative thereof is used in combination with a second therapeutic agent active against the same disease state the dose of each compound may differ from that when the compound is used alone. Appropriate doses will be readily appreciated by those skilled in the art.

No toxicological effects have currently been observed with the compounds of the invention.

All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.

The following non-limiting Examples illustrate the preparation of pharmacologically active compounds of the invention.

EXAMPLES

Abbreviations

Solid phase extraction (SPE); liquid chromatography/mass spectrometry (LCMS, LC/MS & LC-MS); MDAP (Mass Directed Auto Preparation); NMR (nuclear magnetic resonance); s, d, t, dd, m, b (singlet, doublet, triplet, doublet of doublets, multiplet, broad); Ph, Me, Et, Pr, Bu, Bn (phenyl, methyl, ethyl, propyl, butyl, benzyl), tetrahydrofuran (THF),
dichloromethane (DCM), N, N-dimethylformamide (DMF), h (hours),
ethylenediaminetetraacetic acid (EDTA), N-(3dimethylaminopropyl)N'-ethylcarbodiimide
hydrochloride (EDC & EDAC), 4-N,N-dimethylaminopyridine (DMAP), ultraviolet (UV),
room temperature (RT), retention time (Rt), minutes (min), EtOAc (ethyl acetate), Et₂O
(diethyl ether), MeCN (acetonitrile).

**Purification of Reaction Products**

Conventional techniques may be used herein for work up of reactions and purification of
the products of the Examples.

References in the Examples below relating to the drying of organic layers or phases may
refer to drying the solution over magnesium sulfate or sodium sulfate and filtering off the
drying agent in accordance with conventional techniques. Products may generally be
obtained by removing the solvent by evaporation under reduced pressure.

Purification of the Examples may be carried out by conventional methods such as
chromatography and/or recrystallisation using suitable solvents. Chromatographic
methods are known to the skilled person and include e.g. column chromatography, flash
chromatography, HPLC (high performance liquid chromatography), and MDAP (mass
directed autopreparation, also referred to as mass directed LCMS purification). MDAP is
described in e.g. W. Goetzinger *et al.*, *Int. J. Mass Spectrom.*, 2004, **238**, 153-162.

The terms “Biotage®” and “Flash Master II®” when used herein refer to commercially
available automated purification systems using pre-packed silica gel cartridges.

**LCMS**

The following LCMS conditions were used during the preparation of the examples.

**Software**

Waters MassLynx version 4.0 SP2

**Column**

The column used is a Waters Atlantis, the dimensions of which are 4.6mm x 50mm.
The stationary phase particle size is 3μm.

**Solvents**

A : Aqueous solvent = Water + 0.05% Formic Acid
B : Organic solvent = Acetonitrile + 0.05% Formic Acid

**Method**
The generic method used has a 5 minute runtime.

<table>
<thead>
<tr>
<th>Time / min</th>
<th>%B</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>3</td>
</tr>
<tr>
<td>0.1</td>
<td>3</td>
</tr>
<tr>
<td>4</td>
<td>97</td>
</tr>
<tr>
<td>4.8</td>
<td>97</td>
</tr>
<tr>
<td>4.9</td>
<td>3</td>
</tr>
<tr>
<td>5.0</td>
<td>3</td>
</tr>
</tbody>
</table>

All retention times are measured in minutes.

**Description 1**

1-(6-Chloro-1\(H\)-indol-3-yl)-2-methyl-1-propanone (D1)

3M MethylMg bromide in ether (1.7ml, 5.1mmol) was added to a stirred solution of 6-chloroindole (758mg, 5mmol) in dry ether (10ml) under argon producing a two phase mixture and gas evolution. After stirring for 15 minutes 1M zinc chloride in ether (5ml) was added and the mixture stirred for 30 minutes before isobutryl chloride (533mg, 5mmol) was added rapidly with vigorous stirring. The mixture was stirred for 30 minutes and quenched by addition of saturated ammonium chloride solution then diluted with ethyl acetate. The organic phase was dried (magnesium sulphate), evaporated, triturated with ether and filtered to give the title compound as a pink solid (710mg).

LCMS: Rt= 2.89min, [MH]+ 222.18, 224.17.

**Descriptions 2-11**

The following compounds were prepared in an analogous manner to D1 using indole or a 6-substituted indole and an appropriate chloride:

<table>
<thead>
<tr>
<th>Name</th>
<th>Structure</th>
<th>Data</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-(6-Chloro-1(H)-indol-3-yl)-1-propanone (D2)</td>
<td><img src="image1.png" alt="Structure" /></td>
<td>LCMS Rt=2.59 min [MH]+ 208.18, 210.19</td>
</tr>
<tr>
<td>Compound Description</td>
<td>Structure</td>
<td>LCMS Rt</td>
</tr>
<tr>
<td>----------------------</td>
<td>-----------</td>
<td>---------</td>
</tr>
<tr>
<td>1-(6-Chloro-1H-indol-3-yl)-3,3-dimethyl-1-butane (D3)</td>
<td><img src="image1" alt="Structure" /></td>
<td>LCMS Rt=3.26 min [MH]^+ 250.27 252.26</td>
</tr>
<tr>
<td>(6-Chloro-1H-indol-3-yl)(phenyl)methanone (D4)</td>
<td><img src="image2" alt="Structure" /></td>
<td>LCMS Rt=3.07 min [MH]^+ 256.18 258.19</td>
</tr>
<tr>
<td>1-(1H-Indol-3-yl)-2-methyl-1-propanone (D5)</td>
<td><img src="image3" alt="Structure" /></td>
<td>LCMS Rt=2.51 min [MH]^+ 188.2</td>
</tr>
<tr>
<td>1-(6-Bromo-1H-indol-3-yl)-2-methyl-1-propanone (D6)</td>
<td><img src="image4" alt="Structure" /></td>
<td>LCMS Rt=2.34 min [MH]^+ 192.11 194.10</td>
</tr>
<tr>
<td>1-(6-Chloro-1H-indol-3-yl)ethanone (D7)</td>
<td><img src="image5" alt="Structure" /></td>
<td>LCMS Rt=2.34 min [MH]^+ 192.11 194.10</td>
</tr>
<tr>
<td>1-(6-Chloro-1H-indol-3-yl)-2,2-dimethyl-1-propanone (D8)</td>
<td><img src="image6" alt="Structure" /></td>
<td>LCMS Rt=3.14 min [MH]^+ 236.1, 238.1</td>
</tr>
<tr>
<td>1-(6-Fluoro-1H-indol-3-yl)-2-methyl-1-propanone (D9)</td>
<td><img src="image7" alt="Structure" /></td>
<td></td>
</tr>
<tr>
<td>2-Methyl-1-[6-(trifluoromethyl)-1H-indol-3-yl]-1-propanone (D10)</td>
<td><img src="image8" alt="Structure" /></td>
<td></td>
</tr>
</tbody>
</table>

**Description 11**

**6-Chloro-3-(2-methylpropyl)-1H-indole (D11)**

1M Lithium aluminium hydride in THF (7ml, 7mmol) was added to a stirred solution of 1-(6-chloro-1H-indol-3-yl)-2-methyl-1-propanone (may be prepared as described in D1; 705mg, 3.21mmol) in THF (15ml) and heated at 55°C for four hours. The solution was cooled and quenched by careful addition of 2M sodium hydroxide and ether. The organic phase was dried (magnesium sulphate), evaporated and purified on a Biotage column eluting with
(1:9) ethyl acetate/hexane to give the title compound as a colourless oil which crystallised on scratching (663mg).

5 Descriptions 12-17
The following compounds were prepared by reduction of the appropriate ketone as described in the table below using an analogous procedure to that described in D11:

<table>
<thead>
<tr>
<th>Name</th>
<th>Starting Material</th>
<th>Structure</th>
<th>Data</th>
</tr>
</thead>
<tbody>
<tr>
<td>6-Chloro-3-propyl-1H-indole (D12)</td>
<td>D2</td>
<td><img src="structure1.png" alt="Structure" /></td>
<td>LCMS Rt=3.35 min [MH⁺] 194.23, 196.22</td>
</tr>
<tr>
<td>6-Chloro-3-(3,3-dimethylbutyl)-1H-indole (D13)</td>
<td>D3</td>
<td><img src="structure2.png" alt="Structure" /></td>
<td>LCMS Rt=3.98 min [MH⁺] 236.26 238.26</td>
</tr>
<tr>
<td>3-(2-Methylpropyl)-1H-indole (D14)</td>
<td>D5</td>
<td><img src="structure3.png" alt="Structure" /></td>
<td>LCMS Rt=3.44 min [MH⁺] 174.1</td>
</tr>
<tr>
<td>6-Chloro-3-ethyl-1H-indole (D15)</td>
<td>D7</td>
<td><img src="structure4.png" alt="Structure" /></td>
<td>LCMS Rt=3.16 min [MH⁺] 178.06 180.11</td>
</tr>
<tr>
<td>6-Chloro-3-(phenylmethyl)-1H-indole (D16)</td>
<td>D4</td>
<td><img src="structure5.png" alt="Structure" /></td>
<td>LCMS Rt=3.55 min [MH⁺] 242.27 244.30</td>
</tr>
<tr>
<td>6-Fluoro-3-(2-methylpropyl)-1H-indole (D17)</td>
<td>D9</td>
<td><img src="structure6.png" alt="Structure" /></td>
<td></td>
</tr>
</tbody>
</table>

10 Description 18
6-Chloro-3-(2,2-dimethylpropyl)-1H-indole (D18)
1M Lithium aluminium hydride in THF (7.45ml, 7.45mmol) was added to a stirred solution of 1-(6-chloro-1H-indol-3-yl)-2,2-dimethyl-1-propanone (may be prepared as described in D8; 876mg, 3.72mmol) in THF (10ml) and heated at 55°C for 3 hr. More 1M lithium aluminium hydride in THF was added (3.7ml) and mixture heated at 55°C overnight. The solution was cooled and quenched by careful addition of 2M sodium hydroxide and ether. The organic phase was dried, evaporated and purified on a silica column eluting with 15% of ethyl acetate in hexane to give the title compound as oil.

LCMS: Rt=3.84 min, [MH] 220.1, 222.1.

**Description 19**

3-(2-Methylpropyl)-6-(trifluoromethyl)-1H-indole (D19)

2-Methyl-1-[6-(trifluoromethyl)-1H-indol-3-yl]-1-propanone (may be prepared as described in D10; 2.3g, 9mmol) was dissolved in anhydrous THF (30ml), cooled to 0°C and treated with 1M borane in THF (21ml, 21mmol) dropwise at 0°C. The mixture was stirred at room temperature for 1hr, cooled in ice, treated with 1.5M hydrochloric acid (15ml) dropwise, extracted with ethyl acetate, dried over sodium sulphate and evaporated to give the title compound (1.52g) as a green solid.

**Description 20**

6-Bromo-3-(2-methylpropyl)-1H-indole (D20)

D20 was prepared from D6 in an analogous manner to that described for D19.

**Description 21**

(5-Chloro-2-iodophenyl)(3-methyl-2-buten-1-yl)amine (D21)

2M Lithium diisopropylamide in heptane/THF/ethylbenzene (4.16ml, 8.32mmol) were added to a stirred solution of 5-chloro-2-iodoaniline in dry THF (35ml) at -78°C under argon then allowed to warm to 0°C before being cooled to -78°C and 1-bromo-3-methylbut-2-ene (1.364g, 9.15mmol) was added. The resulting solution was stirred for ten minutes at -78°C then allowed to warm to room temperature and stirred for one hour before quenching with water/ether. The organic phase was dried (magnesium sulphate), evaporated and purified.
on a Biotage column eluting with hexane to give the title compound as a pale coloured oil (2.11g).
LCMS: Rt= 4.16min.

Description 22
6-Chloro-3-(1-methylethyl)-1H-indole (D22)

A mixture of (5-chloro-2-iodophenyl)(3-methyl-2-buten-1-yl)amine (may be prepared as described in D21; 2.15g, 6.7mmol), palladium acetate (30mg, 0.134mmol), tetrabutylammonium bromide (2.157g, 6.7mmol) and triethylamine (1.69g, 16.73mmol) in dimethylformamide (12ml) was stirred and heated at 80°C under argon for one hour. The resulting mixture was cooled, diluted with ether/water and the organic phase was dried (magnesium sulphate), evaporated and purified on a Biotage column eluting with ethyl acetate/hexane (1:99) then recrystallised from hexane to give the title compound as a white solid (710mg).
LCMS: Rt= 3.52min, [MH⁺] 194.21, 196.18.

Description 23
1-(6-Chloro-1H-indol-3-yl)-2,2,2-trifluoroethanone (D23)

A solution of 6-chloroindole (1.515g, 10mmol) in ether (10ml) was added to an ice cooled solution of trifluoroacetic anhydride (3.5ml) in ether (30ml) over 2 minutes and the resulting solution left in the fridge overnight. The resulting suspension was evaporated and the residue triturated with ether and filtered to give the title compound as a sandy coloured solid (2.19g).
LCMS: Rt= 3.12min, [MH⁺] 248.14, 250.06.

Description 24
1,1-Dimethylethyl 6-chloro-3-(trifluoroacetyl)-1H-indole-1-carboxylate (D24)
4-Dimethylaminopyridine (2.135g, 17.5mmol) was added to a stirred suspension of 1-(6-chloro-1H-indol-3-yl)-2,2,2-trifluoroethanone (may be prepared as described in D23; 4.33g, 17.5mmol) and di-tert-butyl dicarbonate (3.82g, 17.5mmol) in dichloromethane (50ml) producing a clear solution which was left at room temperature for one hour. The solution was washed with 2M hydrochloric acid, dried (magnesium sulphate), evaporated and the residue triturated with ether and filtered to give the title compound as a white solid (4.71g).

**Description 25**
1,1-Dimethylethyl 6-chloro-3-(2,2,2-trifluoro-1-hydroxyethyl)-1H-indole-1-carboxylate (D25)

![Chemical structure](image)

Sodium borohydride (1g, 26.32mmol) was added to a stirred suspension of 1,1-dimethylethyl 6-chloro-3-(trifluoroacetyl)-1H-indole-1-carboxylate (may be prepared as described in D24; 4.7g, 13.53mmol) in ethanol (60ml) and stirred for one hour. The resulting solution was evaporated and the residue dissolved in ethyl acetate/water and the organic phase dried (magnesium sulphate) and evaporated to give the title compound as a colourless gum (4.7g).

LCMS: Rt= 3.61min.

**Description 26**
1,1-Dimethylethyl 6-chloro-3-(2,2,2-trifluoro-1-[[phenyloxy]carbonothioyl]oxy)ethyl)-1H-indole-1-carboxylate (D26)

![Chemical structure](image)

A solution of phenyl chlorothionoformate (173mg, 1mmol) in dichloromethane (1ml) was added to a solution of 1,1-dimethylethyl 6-chloro-3-(2,2,2-trifluoro-1-hydroxyethyl)-1H-indole-1-carboxylate (may be prepared as described in D25; 350mg, 1mmol) and 4-dimethylaminopyridine (5mg) in pyridine (3ml) and left in the fridge for 3 days. The resulting solution was diluted with ethyl acetate/2M hydrochloric acid and the organic
phase dried (magnesium sulphate), evaporated and purified on a Biotage column eluting
with dichloromethane/hexane (1:4) to give the title compound as a colourless gum
(366mg).
LCMS: Rt= 4.37min.

**Description 27**

1,1-Dimethylethyl 6-chloro-3-(2,2,2-trifluoroethyl)-1H-indole-1-carboxylate (D27)

A mixture of 1,1-dimethylethyl 6-chloro-3-(2,2,2-trifluoro-1-

[(phenyloxy)carbonothioyl]oxy)ethyl)-1H-indole-1-carboxylate (may be prepared as
described in D26; 350mg, 0.72mmol), tributyltin hydride (315mg, 1.08mmol) and 2,2'-
azobis(2-methylpropionitrile) (23mg, 0.14mmol) in toluene (10ml) was stirred and heated
at 80°C for 3 hours. The solution was cooled, evaporated and purified on a Biotage column
eluting with ethyl acetate/hexane (1:49) then on another column eluting with
dichloromethane/hexane (1:4) to give the title compound as a gum which crystallised
(151mg).
LCMS: Rt= 3.98min.

**Description 28**

6-Chloro-3-(2,2,2-trifluoroethyl)-1H-indole (D28)

1,1-Dimethylethyl 6-chloro-3-(2,2,2-trifluoroethyl)-1H-indole-1-carboxylate (may be
prepared as described in D27; 146mg, 0.44mmol) was dissolved in trifluoroacetic
acid/dichloromethane (1:1, 3ml) and left at room temperature for one hour. The solution
was evaporated and the residue triturated with hexane and filtered off to give the title
compound as a white solid (86mg).
LC/MS: Rt= 3.05min, [MH] 232.07, 234.06.

**Description 29**

1-(4-Chloro-2-fluorophenyl)-3-methyl-1-butanone (D29)
4-Chloro-2-fluoro-N-methyl-N-(methyloxy)benzamide (6.1g, 28.05mmol) in THF (20ml) was added over 10 minutes to isobutylmagnesium bromide (prepared from 800mg, 32.92mmol of magnesium and 4.11g, 30mmol of isobutyl bromide in 50ml of THF). Stirred for 30 minutes at room temperature then heated at 60°C for 4 hours. The solution was cooled, diluted with 2M hydrochloric acid/ether and the organic phase dried (magnesium sulphate), evaporated and purified on a Biotage column eluting with ethyl acetate/hexane (5:195) to give the title compound as colourless oil (806mg).

LCMS: Rt = 3.58min.

Description 30

1-(4-Chloro-2-fluorophenyl)-3-methyl-1-butanone hydrazone (D30)

[Chemical structure image]

Hydrazine hydrate (400mg, 8mmol) was added to a solution of 1-(4-chloro-2-fluorophenyl)-3-methyl-1-butanone (may be prepared as described in D29; 800mg, 3.73mmol) in ethanol (10ml) and left at room temperature overnight. The resulting solution was evaporated, dissolved in ethyl acetate/water and the organic phase dried (magnesium sulphate), evaporated and purified on a Biotage column eluting with ethyl acetate/hexane (15:85) to give the title compound as colourless oil (585mg).

LCMS: Rt = 2.90, 2.97min [MH+] 229.22, 231.21.

Description 31

6-Chloro-3-(2-methylpropyl)-1H-indazole (D31)

[Chemical structure image]

1-(4-Chloro-2-fluorophenyl)-3-methyl-1-butanone hydrazone (may be prepared as described in D30; 580mg) in ethylene glycol (5ml) was stirred and heated at 165°C for 3 hours. The solution was cooled diluted with ether/water and the organic phase washed with water, dried (magnesium sulphate), evaporated and purified on a Biotage column eluting with ethyl acetate/hexane (1:7) to give the title compound as white solid (170mg).

LCMS: Rt = 3.10min [MH+] 209.24, 211.23.

Description 32

Ethyl 2-[6-chloro-3-(2-methylpropyl)-1H-indol-1-yl]-1,3-thiazole-4-carboxylate (D32)
A mixture of 6-chloro-3-(2-methylpropyl)-1H-indole (may be prepared as described in D11; 660mg, 3.18mmol), ethyl 2-bromo-4-thiazolecarboxylate (750mg, 3.18mmol), potassium phosphate (1.416g, 6.68mmol), copper(I) iodide (30mg, 0.16mmol) and (1R, 2R)-N,N'-dimethyl-1,2-cyclohexanediamine (53mg, 0.37mmol) in toluene (4ml) was stirred and heated at 110°C under argon for 48 hours when a further quantity of copper(I) iodide (30mg, 0.16mmol) and (1R, 2R)-N,N'-dimethyl-1,2-cyclohexanediamine (53mg, 0.37mmol) was added. After heating for a further 24 hours the mixture was cooled, diluted with ether/water and the organic phase dried (magnesium sulphate), evaporated and purified on a Biotage column eluting with (8:92) ethyl acetate/hexane to give the title compound as a white solid (380mg).


Descriptions 33-43

The following compounds were prepared in an analogous method to that described for D32 using the appropriate indole or indazole and a bromo heterocycle or a bromobenzene. Ethyl 2-bromo-1,3-oxazole-4-carboxylate was prepared as described in Organic Letters 4(17), 2905-2907 (2002).

<table>
<thead>
<tr>
<th>Name</th>
<th>Starting Material</th>
<th>Structure</th>
<th>Data</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ethyl 2-(6-chloro-3-propyl-1H-indol-1-yl)-1,3-thiazole-4-carboxylate (D33)</td>
<td>D12</td>
<td><img src="image" alt="Structure" /></td>
<td>LCMS Rt=4.01 min [MH⁺] 349.22, 351.22</td>
</tr>
<tr>
<td>Ethyl 2-[6-chloro-3-(3,3-dimethylbutyl)-1H-indol-1-yl]-1,3-thiazole-4-carboxylate (D34)</td>
<td>D13</td>
<td><img src="image" alt="Structure" /></td>
<td>LCMS Rt=4.55 min [MH⁺] 391.24, 393.24</td>
</tr>
<tr>
<td>Compound Description</td>
<td>Reference</td>
<td>LCMS Details</td>
<td></td>
</tr>
<tr>
<td>-------------------------------------------------------------------------------------</td>
<td>-----------</td>
<td>--------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Ethyl 2-[3-(2-methylpropyl)-1H-indol-1-yl]-1,3-thiazole-4-carboxylate (D35)</td>
<td>D14</td>
<td>Rt=3.91 min [MH]⁺ 329.30</td>
<td></td>
</tr>
<tr>
<td>Ethyl 2-[6-bromo-3-(2-methylpropyl)-1H-indol-1-yl]-1,3-thiazole-4-carboxylate (D36)</td>
<td>D20</td>
<td>Rt=4.27 min [MH]⁺ 409.14, 410.14</td>
<td></td>
</tr>
<tr>
<td>Ethyl 2-[6-chloro-3-(2-methylpropyl)-1H-indol-1-yl]-1,3-oxazole-4-carboxylate (D37)</td>
<td>D11</td>
<td>Rt=4.18 min [MH]⁺ 347.1, 349.1</td>
<td></td>
</tr>
<tr>
<td>Ethyl 2-[6-chloro-3-(2-methylpropanoyl)-1H-indol-1-yl]-1,3-thiazole-4-carboxylate (D38)</td>
<td>D1</td>
<td>Rt=3.62 min [MH]⁺ 377.19, 379.18</td>
<td></td>
</tr>
<tr>
<td>Ethyl 2-[6-chloro-3-(1-methylethyl)-1H-indol-1-yl]-1,3-thiazole-4-carboxylate (D39)</td>
<td>D22</td>
<td>Rt=4.19 min [MH]⁺ 349.16, 351.15</td>
<td></td>
</tr>
<tr>
<td>Ethyl 2-[6-chloro-3-(phenylmethyl)-1H-indol-1-yl]-1,3-thiazole-4-carboxylate (D40)</td>
<td>D16</td>
<td>Rt=4.16 min [MH]⁺ 397.19, 399.18</td>
<td></td>
</tr>
</tbody>
</table>
Description 44

Ethyl (2-bromo-1,3-thiazol-4-yl)acetate (D44)

\[
\text{Br} \quad \begin{array}{c}
\text{S} \\
\text{N} \\
\text{CO}_2\text{Et}
\end{array}
\]

To an ice cooled suspension of ethyl (2-amino-1,3-thiazol-4-yl)acetate (1g, 5.37mmol) and copper II bromide (1.44g, 6.4mmol) in acetonitrile (6ml), isoamyl nitrite (1.08ml, 8mmol) was added dropwise and the suspension allowed to warm to room temperature with stirring overnight. The solvent was evaporated and the residue dissolved in ethyl acetate/hexane, filtered and the filtrate evaporated to dryness. The residue was purified by flash chromatography on silica gel eluting with 5% methanol/dichloromethane to give the title compound (420mg) as a colourless oil.

LCMS: Rt = 2.45 min [M+H] 252.0.

Description 45

Ethyl 2-[6-fluoro-3-(2-methylpropyl)-1H-indol-1-yl]-1,3-thiazole-4-carboxylate (D45)
A mixture of 6-fluoro-3-(2-methylpropyl)-1H-indole (may be prepared as described in D17; 971mg, 5.07mmol), ethyl 2-bromo-4-thiazolecarboxylate (1g, 4.23mmol), potassium phosphate (1.88g, 8.89mmol), copper(l) iodide (40mg, 0.21mmol) and (1R, 2R)-N,N'-dimethyl-1,2-cyclohexanediomine (120mg, 0.85mmol) in toluene (15ml) was stirred and heated at 110°C under argon for ~20hr. Cooled, filtered through a pad of silica gel using ethyl acetate to rinse, evaporated, and purified on a silica column using 10% of ethyl acetate in hexane. The residue was triturated with hexane to give the title compound as a pale yellow solid.

LCMS: Rt= 4.06 min, [MH]+ 347.2, 348.2.

**Descriptions 46-50**

The following compounds were prepared in an analogous manner to that described in D46 using the appropriate indole and bromo heterocycle:

<table>
<thead>
<tr>
<th>Name</th>
<th>Starting Material</th>
<th>Structure</th>
<th>Data</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methyl 5-[6-chloro-3-(2-methylpropyl)-1H-indol-1-yl]-2-furancarboxylate (D46)</td>
<td>D11</td>
<td><img src="image" alt="Structure" /></td>
<td>LCMS Rt=4.05 min [MH]+ 332, 334</td>
</tr>
<tr>
<td>Ethyl 6-[6-chloro-3-(2-methylpropyl)-1H-indol-1-yl]-2-pyridinecarboxylate (D47)</td>
<td>D11</td>
<td><img src="image" alt="Structure" /></td>
<td>LCMS Rt=4.05 min [MH]+ 332, 334</td>
</tr>
<tr>
<td>Ethyl 2-[6-chloro-3-(2,2-dimethylpropyl)-1H-indol-1-yl]-1,3-thiazole-4-carboxylate (D48)</td>
<td>D18</td>
<td><img src="image" alt="Structure" /></td>
<td>LCMS Rt=4.4 min [MH]+ 377.2, 379.2</td>
</tr>
<tr>
<td>Methyl 2-[6-chloro-3-(2-methylpropyl)-1H-indol-1-yl]-1,3-thiazole-5-carboxylate (D49)</td>
<td>D11</td>
<td><img src="image" alt="Structure" /></td>
<td>LCMS Rt=4.48 min [MH]+ 349.1, 351.1</td>
</tr>
</tbody>
</table>
Description 51
Ethyl 2-(6-chloro-3-ethyl-1H-indol-1-yl)-1,3-thiazole-4-carboxylate (D51)

5 A mixture of 6-chloro-3-ethyl-1H-indole (may be prepared as described in D15; 746mg, 4.15mmol), ethyl 2-bromo-4-thiazolecarboxylate (817 mg, 3.46mmol), potassium phosphate (1.55g, 7.27mmol), copper(I) iodide (33mg, 0.17mmol) and (1R, 2R)-N,N'-dimethyl-1,2-cyclohexanediamine (98, 0.69mmol) in toluene (20ml) was stirred and heated at 110°C under argon for 4hr. More copper(I) iodide, (1R, 2R)-N,N'-dimethyl-1,2-cyclohexanediamine and ethyl 2-bromo-4-thiazolecarboxylate were added and the mixture stirred for a total of 2 days. The solution was cooled, diluted with ethyl acetate/water. The organic phase was washed twice with water, dried (magnesium sulphate), evaporated and purified on the Flash Master II using a gradient of ethyl acetate in hexane. The residue was recrystallised from ether/hexane mixture to give the title compound as a white solid.

10 LCMS: Rt = 4.08min, [MH]⁺ 335.2, 337.2.

Description 52
Ethyl 5-[6-chloro-3-(2-methylpropyl)-1H-indol-1-yl]-2-thiophenecarboxylate (D52)

20 A mixture of 6-chloro-3-(2-methylpropyl)-1H-indole (may be prepared as described in D11; 414mg, 2mmol), ethyl 5-bromothiophene-2-carboxylate (470mg, 2mmol), potassium phosphate (850mg, 4mmol), copper(I) iodide (19mg, 0.1mmol) and (1R, 2R)-N,N'-dimethyl-1,2-cyclohexanediamine (33mg, 0.23mmol) in toluene (10ml) was stirred and heated at 110°C over night. A further quantity of copper(I) iodide (10mg, 0.05mmol) and (1R, 2R)-N,N'-dimethyl-1,2-cyclohexanediamine (17mg, 0.12mmol) was added. After heating for a further 3 hours the mixture was cooled, diluted with ethyl acetate/water and the organic phase dried, evaporated and purified by flash chromatography eluting with 5% ethyl acetate/hexane to give the title compound as a pink oil (380mg).

Description 53
Ethyl 2-[3-(2-methylpropyl)-6-(trifluoromethyl)-1H-indol-1-yl]-1,3-thiazole-4-carboxylate (D53)

5

D53 was prepared from D19 in an analogous manner to that described for D52.

Description 54
Ethyl 2-[[6-chloro-3-(2-methylpropyl)-1H-indol-1-yl]methyl]-1,3-thiazole-4-carboxylate (D54)

10

60% Sodium hydride (100mg, 2.5mmol) was added to a stirred solution of 6-chloro-3-(2-methylpropyl)-1H-indole (may be prepared as described in D11; 519mg, 2.5mmol) in dimethylformamide (8ml) under argon and stirred for 10 minutes when ethyl 2-(bromomethyl)-1,3-thiazole-4-carboxylate (625mg, 2.5mmol) were added. The solution was stirred at room temperature for one hour then diluted with ether/water. The organic phase was washed three times with water, dried (magnesium sulphate), evaporated and purified on a Biotage column eluting with (20:80) ethyl acetate/hexane then triturated with hexane to give the title compound as a white solid (388mg).

15


Description 55
1-[2-(Ethenylamino)-4-methylphenyl]-3-methyl-2-butanone (D55)

20

A solution of 6-methyl-1H-indole (0.47 ml, 3.81 mmol) in Et₂O (9.9 ml) was stirred at 0 °C under an atmosphere of argon. A solution of methyl magnesium bromide in Et₂O (3M, 1.29 ml, 3.89 mmol) was added slowly to the reaction mixture over a period of 5 minutes. A slight exotherm was observed. The reaction mixture was stirred for 30 minutes allowing the reaction contents to warm to room temperature. After this time, zinc chloride in Et₂O
(1M, 3.81 ml, 3.81 mmol) was added slowly to the reaction mixture. Green precipitate observed. The mixture was stirred at room temperature for a further 15 minutes. After this time, 2-methylpropanoyl chloride (0.40 ml, 3.81 mmol) was added to the reaction mixture. The mixture was stirred for 15 minutes at room temperature. The reaction was monitored by LC-MS. The reaction was quenched by the dropwise addition of saturated ammonium chloride (10 ml). The organics were extracted with EtOAc, dried over magnesium sulfate, filtered and concentrated under reduced pressure to give an orange solid. The crude product was recrystallized from EtO to give a white solid, 1-[2-(ethenylamino)-4-methylphenyl]-3-methyl-2-butanone (0.43 g, 56%).

**LCMS Rt = 2.64 min, [M+H] 202, 203.**

**Description 56**

**Ethynyl[5-methyl-2-(3-methylbutyl)phenyl]amine (D56)**

A solution of lithium aluminium hydride in THF (1M, 4.10 ml, 1.94 mmol) was added slowly to a stirred solution of 1-[2-(ethenylamino)-4-methylphenyl]-3-methyl-2-butanone (may be prepared as described in D55; 0.43 g, 2.14 mmol) in dry THF (5 ml) at 0 °C under an atmosphere of argon. Slight effervescence observed. The reaction mixture was left stirring at 0 °C for 30 min under an atmosphere of argon. After this time, the reaction mixture was heated to 50 °C for 90 minutes. The reaction was monitored by LC-MS. The reaction mixture was cooled to 0 °C and quenched by the dropwise addition of water. Colour change of pink to green observed. The solution was stirred at 0 °C for further 10 minutes and then allowed to warm to room temperature. The organics were extracted using EtOAc. The combined organics were dried over magnesium sulfate, filtered and concentrated under reduced pressure to give a brown oil, ethynyl[5-methyl-2-(3-methylbutyl)phenyl]amine (0.27 g, 67%).

**LCMS Rt = 3.53 min, [M+H] 188, 189.**

**Description 57**

**Ethyl 2-(ethenyl[5-methyl-2-(3-methylbutyl)phenyl]amino)-1,3-thiazole-4-carboxylate (D57)**
A solution of ethenyl[5-methyl-2-(3-methylbutyl)phenyl]amine (may be prepared as described in D56; 0.27 g, 1.43 mmol), ethyl 2-bromo-1,3-thiazole-4-carboxylate (0.34 g, 1.43 mmol), copper iodide (0.017 g, 0.09 mmol), (1R, 2R) trans-diaminomethylcyclohexane (0.030 g, 0.21 mmol) and potassium phosphate (0.64 g, 3.00 mmol) in PhCH₃ (2.8 ml) was stirred at 110 °C for 16 hours under an atmosphere of argon. The reaction was monitored by LC-MS. After this time, further ethyl 2-bromo-1,3-thiazole-4-carboxylate (0.17 g, 0.72 mmol) was added to the reaction mixture and the mixture stirred at 110 °C for a further 1 hour. After this time, the reaction mixture was allowed to cool to room temperature, and was then partitioned between EtOAc and water. The organics were washed with water, dried over magnesium sulfate, filtered and concentrated under reduced pressure to give brown oil. The residue was purified using column chromatography [SiO₂, Hexane:EtOAc (1:0 to 9:1)] to give ethyl 2-{ethenyl[5-methyl-2-(3-methylbutyl)phenyl]amino}-1,3-thiazole-4-carboxylate (0.059 g, 12%). LCMS Rt = 4.27 min, [M+H] 343, 344.

**Example 1**

2-(6-Chloro-3-propyl-1H-indol-1-yl)-1,3-thiazole-4-carboxylic acid (E1)

![Chemical Structure](https://example.com/structure.png)

Ethyl 2-(6-chloro-3-propyl-1H-indol-1-yl)-1,3-thiazole-4-carboxylate (may be prepared as described in D33; 80mg, 0.23mmol) was dissolved in hot ethanol (5ml) and 2M sodium hydroxide (1ml) added and left for 15 minutes. The solution was evaporated to dryness, dissolved in ethyl acetate/2M hydrochloric acid and the organic phase dried (magnesium sulphate), evaporated and triturated with ether to give the title compound as a white solid (54mg).

LC/MS: Rt= 3.35min, [MH⁺] 321.19, 323.18.

**Examples 2-15**

The following compounds were prepared by treating the appropriate ester indicated in the table below with sodium hydroxide using an analogous procedure to that described for E1:
<table>
<thead>
<tr>
<th>Name</th>
<th>Starting Material</th>
<th>Structure</th>
<th>Data</th>
</tr>
</thead>
<tbody>
<tr>
<td>2-[6-Chloro-3-(3,3-dimethylbutyl)-1H-indol-1-yl]-1,3-thiazole-4-carboxylic acid (E2)</td>
<td>D34</td>
<td><img src="image1" alt="Structure Image" /></td>
<td>LCMS Rt=4.03 min [MH](^+) 363.18, 365.23</td>
</tr>
<tr>
<td>2-[6-Chloro-3-(1-methylethyl)-1H-indol-1-yl]-1,3-thiazole-4-carboxylic acid (E3)</td>
<td>D39</td>
<td><img src="image2" alt="Structure Image" /></td>
<td>LCMS Rt=3.53 min [MH](^+) 321.15, 323.16</td>
</tr>
<tr>
<td>2-[6-Bromo-3-(2-methylpropyl)-1H-indol-1-yl]-1,3-thiazole-4-carboxylic acid (E4)</td>
<td>D36</td>
<td><img src="image3" alt="Structure Image" /></td>
<td>LCMS Rt=3.65 min [MH](^+) 379.10, 382.15</td>
</tr>
<tr>
<td>2-[6-Chloro-3-(2-methylpropyl)-1H-indol-1-yl]-1,3-oxazole-4-carboxylic acid (E5)</td>
<td>D37</td>
<td><img src="image4" alt="Structure Image" /></td>
<td>LCMS Rt=3.57 min [MH](^+) 319.20, 321.19</td>
</tr>
<tr>
<td>2-[6-Chloro-3-(2-methylpropyl)-1H-indol-1-yl][methyl]-1,3-thiazole-4-carboxylic acid (E6)</td>
<td>D54</td>
<td><img src="image5" alt="Structure Image" /></td>
<td>LCMS Rt=3.31 min [MH](^+) 349.23, 351.22</td>
</tr>
<tr>
<td>2-[6-Chloro-3-(2-methylpropanoyl)-1H-indol-1-yl]-1,3-thiazole-4-carboxylic acid (E7)</td>
<td>D38</td>
<td><img src="image6" alt="Structure Image" /></td>
<td>LCMS Rt=2.97 min [MH](^+) 349.15, 351.15</td>
</tr>
<tr>
<td>Compound</td>
<td>Code</td>
<td>Structure</td>
<td>LCMS Rt</td>
</tr>
<tr>
<td>-------------------------------------------------------------------------</td>
<td>------</td>
<td>-----------</td>
<td>---------</td>
</tr>
<tr>
<td>2-[6-Chloro-3-(phenylethyl)-1H-indol-1-yl]-1,3-thiazole-4-carboxylic acid (E8)</td>
<td>D40</td>
<td><img src="image" alt="Structure D40" /></td>
<td>3.54 min</td>
</tr>
<tr>
<td>2-[6-Chloro-3-(2,2,2-trifluoroethyl)-1H-indol-1-yl]-1,3-thiazole-4-carboxylic acid (E9)</td>
<td>D41</td>
<td><img src="image" alt="Structure D41" /></td>
<td>3.11 min</td>
</tr>
<tr>
<td>2-[3-(2-Methylpropyl)-1H-indol-1-yl]-1,3-thiazole-4-carboxylic acid (E10)</td>
<td>D35</td>
<td><img src="image" alt="Structure D35" /></td>
<td>3.27 min</td>
</tr>
<tr>
<td>2-[6-Chloro-3-(2-methylpropyl)-1H-indazol-1-yl]-1,3-thiazole-4-carboxylic acid (E11)</td>
<td>D43</td>
<td><img src="image" alt="Structure D43" /></td>
<td>3.51 min</td>
</tr>
<tr>
<td>2-[6-Chloro-3-(2,2-dimethylpropyl)-1H-indol-1-yl]-1,3-thiazole-4-carboxylic acid (E12)</td>
<td>D48</td>
<td><img src="image" alt="Structure D48" /></td>
<td>3.86 min</td>
</tr>
<tr>
<td>2-[3-(2-Methylpropyl)-6-(trifluoromethyl)-1H-indol-1-yl]-1,3-thiazole-4-carboxylic acid (E13)</td>
<td>D53</td>
<td><img src="image" alt="Structure D53" /></td>
<td>3.66 min</td>
</tr>
<tr>
<td>3-[6-Chloro-3-(2-methylpropyl)-1H-indol-1-yl]benzoic acid (E14)</td>
<td>D42</td>
<td><img src="image" alt="Structure D42" /></td>
<td>3.92 min</td>
</tr>
</tbody>
</table>
Example 16
2-[6-Fluoro-3-(2-methylpropyl)-1H-indol-1-yl]-1,3-thiazole-4-carboxylic acid (E16)

Ethyl 2-[6-fluoro-3-(2-methylpropyl)-1H-indol-1-yl]-1,3-thiazole-4-carboxylate (may be prepared as described in D45; 857mg, 2.47mmol) was dissolved in ethanol (8ml) and 2M sodium hydroxide (3ml) added and stirred at 50°C for 2hr. The solution was cooled, evaporated to dryness, dissolved in ethyl acetate and acidified with 2M hydrochloric acid, extracted with ethyl acetate (x3). The combined organic phase was dried (MgSO₄), evaporated and triturated with hexane/ether to give the title compound as a pale yellow solid (610mg).

LCMS: Rf= 3.41min, [MH⁺] 319.2, 320.2.

Example 17
2-[6-Chloro-3-(2-methylpropyl)-1H-indol-1-yl]-1,3-thiazole-4-carboxylic acid (E17)

Ethyl 2-[6-chloro-3-(2-methylpropyl)-1H-indol-1-yl]-1,3-thiazole-4-carboxylate (may be prepared as described in D32; 2.6g not clean) was dissolved in ethanol (20ml) and 2M sodium hydroxide (10ml) added and stirred at 50°C for 1hr. The solution was cooled, evaporated to dryness, diluted with water and extracted with diethyl ether (x3). The aqueous phase was then acidified with 2M hydrochloric acid, extracted with ethyl acetate (x3), the organic phase was dried (MgSO₄) and evaporated to give the title compound as pale yellow solid (1.5g)

LCMS: Rf= 3.67min, [MH⁺] 335.1, 337.1, [MH⁻] 333.2, 335.1
Examples 18-21
The following compounds were prepared from the starting material indicated in the table below in an analogous manner to that described in E17 except that E19 and E20 were only neutralised with hydrochloric acid:

<table>
<thead>
<tr>
<th>Name</th>
<th>Starting Material</th>
<th>Structure</th>
<th>Data</th>
</tr>
</thead>
<tbody>
<tr>
<td>5-[6-Chloro-3-(2-methylpropyl)-1H-indol-1-yl]-2-furancarboxylic acid (E18)</td>
<td>D46</td>
<td><img src="image" alt="Structure" /></td>
<td>LCMS Rt=3.66 min [MH]&lt;sup&gt;+&lt;/sup&gt; 318.1, 320.1, [MH]&lt;sup&gt;−&lt;/sup&gt; 316.2, 318.2</td>
</tr>
<tr>
<td>6-[6-Chloro-3-(2-methylpropyl)-1H-indol-1-yl]-2-pyridinecarboxylic acid (E19)</td>
<td>D47</td>
<td><img src="image" alt="Structure" /></td>
<td>LCMS Rt=3.54 min [MH]&lt;sup&gt;+&lt;/sup&gt; 329, 331, [MH]&lt;sup&gt;−&lt;/sup&gt; 327, 329</td>
</tr>
<tr>
<td>2-(6-Chloro-3-ethyl-1H-indol-1-yl)-1,3-thiazole-4-carboxylic acid (E20)</td>
<td>D51</td>
<td><img src="image" alt="Structure" /></td>
<td>LCMS Rt=3.36 min [MH]&lt;sup&gt;+&lt;/sup&gt; 307.2, 309.2,</td>
</tr>
<tr>
<td>2-[6-Chloro-3-(2-methylpropyl)-1H-indol-1-yl]-1,3-thiazole-5-carboxylic acid (E21)</td>
<td>D49</td>
<td><img src="image" alt="Structure" /></td>
<td>LCMS Rt=4.01 min [MH]&lt;sup&gt;+&lt;/sup&gt; 335.1, 337.1</td>
</tr>
</tbody>
</table>

Example 22
5-[6-Chloro-3-(2-methylpropyl)-1H-indol-1-yl]-2-thiophenecarboxylic acid (E22)

![Structure](image)

Ethyl 5-[6-chloro-3-(2-methylpropyl)-1H-indol-1-yl]-2-thiophenecarboxylate (may be prepared as described in D52; 500mg not clean) was dissolved in ethanol (2ml) and 2M sodium hydroxide (1ml) added and stirred at room temperature for 1hr. The solution was cooled, evaporated to dryness, acidified with 2M and extracted with ethyl acetate. The organic phase was dried (MgSO₄), evaporated and purified on MDAP to give the title compound as a white solid (8mg).
LCMS: Rt= 3.84 min, [MH]+ 334.1.

Example 23
2-[6-Chloro-3-(2-methylpropyl)-1H-indol-1-yl]-N-(phenylsulfonyl)-1,3-thiazole-4-carboxamide (E23)

A mixture of 2-[6-chloro-3-(2-methylpropyl)-1H-indol-1-yl]-1,3-thiazole-4-carboxylic acid (may be prepared as described in E17; 112mg, 0.33mmol), benzenesulphonamide (63mg, 0.4mmol) EDAC (96mg, 0.5mmol) and 4-dimethylaminopyridine (2mg) in dichloromethane (3ml) was stirred at room temperature for 6 hours then diluted with ethyl acetate and washed twice with 2M sodium hydroxide and once with 2M hydrochloric acid. The organic phase was dried (magnesium sulphate), evaporated and purified on a Biotage column eluting with ethyl acetate/hexane (2:3). The product was triturated with ether to give the title compound as a white solid (53mg).

LCMS: Rt= 4.10min, [MH]+ 474.19, 476.18.

Example 24
2-{Ethenyl[5-methyl-2-(3-methylbutyl)phenyl]amino}-1,3-thiazole-4-carboxylic acid (E24)

A solution of ethyl 2-{ethenyl[5-methyl-2-(3-methylbutyl)phenyl]amino}-1,3-thiazole-4-carboxylate (may be prepared as described in D57; 0.059 g, 0.17 mmol) and 2M sodium hydroxide (0.36 ml, 0.72 mmol) in EtOH (0.5 ml) was stirred at 90°C for 1 hour. The reaction was monitored by LC-MS. After this time, the reaction mixture was allowed to cool to room temperature. The reaction mixture was diluted with water and acidified to pH 1 using 2M HCl. The organics were extracted with EtOAc. The combined organics were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was triturated using hexane to give a white solid, 2-{ethenyl[5-methyl-2-(3-methylbutyl)phenyl]amino}-1,3-thiazole-4-carboxylic acid (0.02 g, 37%).
LCMS Rt = 3.61 min, [M+H] 315.

It is to be understood that the present invention covers all combinations of particular and preferred subgroups described herein above.

ASSAYS FOR DETERMINING BIOLOGICAL ACTIVITY

The compounds of formula (I) can be tested using the following assays to demonstrate their prostanoid antagonist or agonist activity in vitro and in vivo and their selectivity.

Prostaglandin receptors that may be investigated are DP, EP₁, EP₂, EP₃, EP₄, FP, IP and TP.

Biological Activity at EP₁ and EP₃ Receptors

The ability of compounds to antagonise EP₁ & EP₃ receptors may be demonstrated using a functional calcium mobilisation assay. Briefly, the antagonist properties of compounds are assessed by their ability to inhibit the mobilisation of intracellular calcium ([Ca²⁺]ᵢ) in response to activation of EP₁ or EP₃ receptors by the natural agonist hormone prostaglandin E₂ (PGE₂). Increasing concentrations of antagonist reduce the amount of calcium that a given concentration of PGE₂ can mobilise. The net effect is to displace the PGE₂ concentration-effect curve to higher concentrations of PGE₂. The amount of calcium produced is assessed using a calcium-sensitive fluorescent dye such as Fluo-4, AM and a suitable instrument such as a Fluorimetric Imaging Plate Reader (FLIPR). Increasing amounts of [Ca²⁺]ᵢ produced by receptor activation increase the amount of fluorescence produced by the dye and give rise to an increasing signal. The signal may be detected using the FLIPR instrument and the data generated may be analysed with suitable curve-fitting software.

The human EP₁ or EP₃ calcium mobilisation assay (hereafter referred to as ‘the calcium assay’) utilises Chinese hamster ovary-K1 (CHO-K1) cells into which a stable (pCIN;
BioTechniques 20(1996): 102-110) vector containing either EP₁ or EP₃ cDNA has previously been transfected. Cells are cultured in suitable flasks containing culture medium such as DMEM:F-12 supplemented with 10% v/v foetal calf serum, 2mM L-glutamine, 0.25mg/ml genetin, 100µM flurbiprofen and 10µg/ml puromycin.

For assay, cells are harvested using a proprietary reagent that dislodges cells such as Versene. Cells are re-suspended in a suitable quantity of fresh culture media for introduction into a 384-well plate. Following incubation for 24 hours at 37°C the culture media is replaced with a medium containing Fluo-4 and the detergent pluronic acid, and a further incubation takes place. Concentrations of compounds are then added to the plate in order to construct concentration-effect curves. This may be performed on the FLIPR in order to assess the agonist properties of the compounds. Concentrations of PGE₂ are then added to the plate in order to assess the antagonist properties of the compounds.
The data so generated may be analysed by means of a computerised curve-fitting routine. The concentration of compound that elicits a half-maximal inhibition of the calcium mobilisation induced by PGE$_2$ (pIC$_{50}$) may then be estimated.

**Binding Assay for the Human Prostanoid EP$_1$ Receptor**


Compound potencies are determined using a radioligand binding assay. In this assay compound potencies are determined from their ability to compete with tritiated prostaglandin E$_2$ ($[^3]$H-PGE$_2$) for binding to the human EP$_1$ receptor.

This assay utilises Chinese hamster ovary-K1 (CHO-K1) cells into which a stable vector containing the EP$_1$ cDNA has previously been transfected. Cells are cultured in suitable flasks containing culture medium such as DMEM:F-12 supplemented with 10% v/v foetal calf serum, 2mM L-glutamine, 0.25mg/ml geneticin, 10μg/ml puromycin and 10μM indomethacin.

Cells are detached from the culture flasks by incubation in calcium and magnesium free phosphate buffered saline containing 1 mM disodium ethylenediaminetetraacetic acid (Na$_2$EDTA) and 10μM indomethacin for 5 min. The cells are isolated by centrifugation at 250xg for 5mins and suspended in an ice cold buffer such as 50 mM Tris, 1mM Na$_2$EDTA, 140mM NaCl, 10μM indomethacin (pH 7.4). The cells are homogenised using a Polytron tissue disrupter (2x10s burst at full setting), centrifuged at 48,000xg for 20mins and the pellet containing the membrane fraction is washed (optional) three times by suspension and centrifugation at 48,000xg for 20mins. The final membrane pellet is suspended in an assay buffer such as 10mM 2-[N-morpholino]ethanesulphonic acid, 1mM Na$_2$EDTA, 10mM MgCl$_2$ (pH 6). Aliquots are frozen at −80°C until required.

For the binding assay the cell membranes, competing compounds and $[^3]$H-PGE$_2$ (3nM final assay concentration) are incubated in a final volume of 100μl for 30 min at 30°C. All reagents are prepared in assay buffer. Reactions are terminated by rapid vacuum filtration over GF/B filters using a Brandell cell harvester. The filters are washed with ice cold assay buffer, dried and the radioactivity retained on the filters is measured by liquid scintillation counting in Packard TopCount scintillation counter.

The data are analysed using non linear curve fitting techniques to determine the concentration of compound producing 50% inhibition of specific binding (IC$_{50}$).
Results

The compounds of examples 1-24 were tested in the binding assay for the human prostanooid EP₁ receptor. The results are expressed as pIC₅₀ values. A pIC₅₀ is the negative logarithm₁₀ of the IC₅₀. The results given are averages of a number of experiments. The compounds of examples 1-24 had a pIC₅₀ value ≥6. More particularly, the compounds of examples 1-6, 11-13, 16-19, and 21-24 exhibited a pIC₅₀ value ≥7.

The compounds of examples 1-24 were tested in the human EP₁ calcium mobilisation assay. The results are expressed as functional pKᵢ values. A functional pKᵢ is the negative logarithm₁₀ of the antagonist dissociation constant as determined in the human EP₁ calcium mobilisation assay. The results given are averages of a number of experiments. The compounds of examples 1-24 exhibited a functional pKᵢ value ≥6.0. More particularly, the compounds of examples 1-8, 10-13, and 15-24 exhibited a functional pKᵢ value of ≥ 7.0.

The compounds of examples 1-24 were tested in the human EP₃ calcium mobilisation assay. The results are expressed as functional pKᵢ values. A functional pKᵢ is the negative logarithm₁₀ of the antagonist dissociation constant as determined in the human EP₃ calcium mobilisation assay. The results given are averages of a number of experiments. The compounds of examples 1-24 exhibited a functional pKᵢ value of ≤ 6.7. The compounds of examples 7 and 20 exhibited a functional pKᵢ value of ≤ 5.7.

The application of which this description and claims forms part may be used as a basis for priority in respect of any subsequent application. The claims of such subsequent application may be directed to any feature or combination of features described herein. They may take the form of product, composition, process, or use claims and may include, by way of example and without limitation the following claims:
1. A compound of formula (I):

wherein
R\(^1\) represents hydrogen, methyl, -CF\(_3\), chlorine, fluorine or bromine;
R\(^2\) represents ethyl, propyl, isopropyl, isobutyl, -CH\(_2\)-t-butyl, -(CH\(_2\))\(_2\)-t-butyl, optionally substituted -CH\(_2\)-phenyl, -CH\(_2\)-CF\(_3\) or -CO-isopropyl;
X represents CH or N;
R\(^3\) represents a group of formula (i)-(ix):

(i) \(\text{O} \bigtriangleup \text{N}\)  
(ii) \(\text{S} \bigtriangleup \text{N}\)  
(iii) \(\text{S} \bigtriangleup \text{N} \bigtriangleup \text{COOH}\)  
(iv) \(\text{N}\)  
(v) \(\text{O} \bigtriangleup \text{R}\)  
(vi) \(\text{S} \bigtriangleup \text{R}\)  
(vii) \(\text{S} \bigtriangleup \text{R} \bigtriangleup \text{COOH}\)  
(viii) \(\text{N} \bigtriangleup \text{R} \bigtriangleup \text{COOH}\)  
(ix) \(\text{R} \bigtriangleup \text{COOH}\)  

R\(^4\) represents -COOH, -CO-NH-SO\(_2\)R\(^5\) or tetrazole;
R\(^5\) represents C\(_1-3\) alkyl, optionally substituted phenyl or 2,4-dimethylisoxazol-4-yl; such that when R\(^1\) represents hydrogen, R\(^2\) represents isobutyl;
or derivatives thereof.

2. A compound according to claim 1 selected from the compounds of Examples 1 to 24 or a pharmaceutically acceptable derivative thereof.

3. A pharmaceutical composition comprising a compound according to claim 1 or claim 2 or a pharmaceutically acceptable derivative thereof together with a pharmaceutical carrier and/or excipient.
4. A compound according to claim 1 or claim 2 or a pharmaceutically acceptable derivative thereof for use as an active therapeutic substance.

5. A compound according to claim 1 or claim 2 or a pharmaceutically acceptable derivative thereof for use in the treatment of a condition which is mediated by the action of PGE$_2$ at EP$_1$ receptors.

6. A method of treating a human or animal subject suffering from a condition which is mediated by the action of PGE$_2$ at EP$_1$ receptors which comprises administering to said subject an effective amount of a compound according to claim 1 or claim 2 or a pharmaceutically acceptable derivative thereof.

7. A method of treating a human or animal subject suffering from a pain, or an inflammatory, immunological, bone, neurodegenerative or renal disorder, which method comprises administering to said subject an effective amount of a compound according to claim 1 or claim 2 or a pharmaceutically acceptable derivative thereof.

8. A method of treating a human or animal subject suffering from inflammatory pain, neuropathic pain or visceral pain which method comprises administering to said subject an effective amount of a compound according to claim 1 or claim 2 or a pharmaceutically acceptable derivative thereof.

9. Use of a compound according to claim 1 or claim 2 or a pharmaceutically acceptable derivative thereof for the manufacture of a medicament for the treatment of a condition which is mediated by the action of PGE$_2$ at EP$_1$ receptors.

10. Use of a compound according to claim 1 or claim 2 or a pharmaceutically acceptable derivative thereof for the manufacture of a medicament for the treatment or prevention of a condition such as a pain, or an inflammatory, immunological, bone, neurodegenerative or renal disorder.

11. Use of a compound according to claim 1 or claim 2 or a pharmaceutically acceptable derivative thereof for the manufacture of a medicament for the treatment or prevention of a condition such as inflammatory pain, neuropathic pain or visceral pain.
INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER

<table>
<thead>
<tr>
<th>INV.</th>
<th>C07D209/08</th>
<th>C07D401/04</th>
<th>C07D405/04</th>
<th>C07D409/04</th>
<th>C07D413/04</th>
</tr>
</thead>
<tbody>
<tr>
<td>INV.</td>
<td>C07D417/04</td>
<td>C07D417/06</td>
<td>A61K31/427</td>
<td>A61K31/404</td>
<td>A61K31/4439</td>
</tr>
<tr>
<td></td>
<td>A61P29/00</td>
<td>A61P25/02</td>
<td>A61P37/00</td>
<td>A61P25/28</td>
<td>A61P13/12</td>
</tr>
</tbody>
</table>

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, BEILSTEIN Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>WO 2005/040128 A (GLAXO GROUP LTD [GB]; GIBLIN GERARD MARTIN PAUL [GB]; HALL ADRIAN [GB]) 6 May 2005 (2005-05-06) cited in the application the whole document</td>
<td>1-11</td>
</tr>
</tbody>
</table>

Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:

*A* document defining the general state of the art which is not considered to be of particular relevance

*E* earlier document but published on or after the international filing date

*L* document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

*O* document referring to an oral disclosure, use, exhibition or other means

*P* document published prior to the international filing date but later than the priority date claimed

** later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

*F* document member of the same patent family

Date of the actual completion of the international search | 17 October 2007 |

Date of mailing of the international search report | 29/10/2007 |

Name and mailing address of the ISA/European Patent Office, P.O. Box 5018 Patentlaan 2 NL-2280 HV Rijswijk Tel. (+31-70) 340-2940, Tx. 31 651 epo nl, Fax (+31-70) 340-3016

Authorized officer | MATES VALDIVIELSO, J

Form: PCT/ISA/350 (second sheet) (April 2005)
INTERNATIONAL SEARCH REPORT

Box II  Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☑ Claims Nos.: because they relate to subject-matter not required to be searched by this Authority, namely:
   Although claims 6-8 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

2. ☐ Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. ☐ Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III  Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant’s protest.

☐ No protest accompanied the payment of additional search fees.
## INTERNATIONAL SEARCH REPORT

**Information on patent family members**

<table>
<thead>
<tr>
<th>Patent document cited in search report</th>
<th>Publication date</th>
<th>Patent family member(s)</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>JP 2007509104 T</td>
<td>12-04-2007</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2345474 A1</td>
<td>06-04-2000</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CN 1328550 A</td>
<td>26-12-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HU 0103511 A2</td>
<td>28-01-2002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 0018744 A1</td>
<td>06-04-2000</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2002525361 T</td>
<td>13-08-2002</td>
</tr>
</tbody>
</table>